VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Exploring the use of olaparib in advanced breast cancer

Gaia Griguolo, MD, of the Istituto Oncologico Veneto, Padua, Italy, discusses the use of olaparib in advanced breast cancer. The OlympiAD trial (NCT02000622) compared the use of olaparib against standard treatment in metastatic triple-negative breast cancer (TNBC) or HER2+ refractory patients and showed an improvement in progression free survival and an increased overall survival in TNBC subgroups. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter